Back to rankings

Exponent, Inc. (EXPO)

NEUTRAL
IndustrialsEngineering & ConstructionUnited States

Fundamental

65

Price

$69.92

Market Cap

$3.39B

Part 1 · What the company is worth

Overview

Exponent, Inc., together with its subsidiaries, operates as a science and engineering consulting company in the United States and internationally. The company operates in two segments, Engineering and Other Scientific, and Environmental and Health. It provides services in the areas of biomechanics, biomedical engineering and sciences, civil and structural engineering, construction consulting, data sciences, electrical engineering and computer science, human factors, materials and corrosion engineering, mechanical engineering, metallurgical and corrosion engineering polymer and chemistry, thermal sciences, and vehicle engineering. The company also offers services in the areas of chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences, and health sciences. In addition, it provides proactive and reactive product safety, litigation support, and technical, regulatory services. It serves clients in chemical, construction, consumer products, energy, food, beverage and nutrition, government, life sciences, insurance, manufacturing, technology, industrial equipment, transportation, and other sectors. The company was formerly known as The Failure Group, Inc. and changed its name to Exponent, Inc. in 1998. The company was founded in 1967 and is headquartered in Menlo Park, California.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Balance Sheet & Liquidity

Revenue

$632M

Trailing 12 months (through 7/3/2026)

Net Income

$112M

Trailing 12 months (through 7/3/2026)

Free Cash Flow

$122M

Total Equity

$390M

Total Liabilities

$387M

Current Ratio

1.98

Interest Coverage

-

Debt/EBITDA

0.62

Earnings Per Share

Revenue & Net Income

Free Cash Flow

Income Breakdown

Historical statement

Margins over time

Debt over time

How heavy the debt is

Growth grid

Growth — Revenue

Fair Value Estimation

General caseFairly Valued

Fair Value

$63.65

Current Price

$69.92

Margin of Safety

-9.9%

Fair Value Range

$45.42 - $81.89

Estimation Methods

Analyst price target:$84.00
Discounted cash flow (DCF):$62.39
Earnings multiple (P/E):$59.46
Graham growth formula:$40.11
Earnings power value (EPV):$22.15
Justified P/B:$43.75
Dividend discount (Gordon):$29.62
P/FFO, funds from operations:Not enough data to compute it
Mid-cycle earnings:$60.80
Revenue multiple:Not enough data to compute it
Analyst Consensus:Strong Buy (8B / 2H / 0S)
Last Earnings Surprise:+6.95%

Valuation Metrics

P/E Ratio

31.88

ROE

27.2%

P/B Ratio

11.66

P/FCF

31.00

Gross Margin

-

ROIC

20.4%

Profitability Radar

Value Creation (Economic Moat)

ROIC

20.4%

WACC

8.1%

ROIC − WACC

+12.3 pp

ROIC exceeds the cost of capital — the company is creating value for shareholders.

Fundamental Analysis Criteria

Passed (18)

  • EPS shows upward trend
  • Price CAGR 8.82%
  • ROIC 20.4%
  • Debt/Equity ratio
  • Operating Margin 20.2%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • ROE 27.9%
  • Revenue Growth 5Y 7.8%
  • Analyst Consensus 80% Buy
  • Earnings Surprise avg 4.3%
  • Earnings Quality (OCF/NI) 1.06
  • Share Dilution -0.9%
  • Piotroski F-Score 5/9

Failed (7)

  • EPS CAGR 2.16%
  • P/FCF 31.00
  • P/B Ratio 11.66
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • PEG Ratio 4.90
  • Net Margin Trend 17.7% vs 18.3%

Unavailable (3)

  • Gross Margin NaN%
  • Dividend Payout NaN%
  • Interest Coverage

Piotroski F-Score

5/9

Mixed signals: some areas need attention

score
criteria

Earnings Quality

1.06

High quality: earnings backed by cash

Share Dilution

-0.9%

Buying back shares. Shareholder friendly

Governance

Executive Team

NameTitleAge
Dr. Catherine Ford Corrigan P.E., Ph.D.CEO & Director56
Mr. Richard L. Schlenker Jr.Executive VP, Corporate Secretary & Director59
Dr. Maureen T. F. Reitman F.S.P.E., P.E., Sc.D.Group Vice President56
Dr. Joseph Rakow Ph.D.Group Vice President48
Dr. Joseph Sala Ph.D.Group Vice President48
Dr. John D. Pye P.E., Ph.D.President54
Dr. Bernard Ross P.E., Ph.D.Co-Founder & Principal Engineer-
Mr. Eric R. AndersonChief Financial Officer50
Ms. Gina FlynnVP of Legal & General Counsel-
Mr. Brian KundertChief Human Resources Officer50

Audit Risk

9

Board Risk

2

Compensation Risk

4

Shareholder Rights Risk

2

Part 2 · The price and when to enter

This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.

Latest News

Recent headlines for EXPO, sourced from Markets Gazette.

No recent news for EXPO.